Join

Compare · NTRA vs NVTA

NTRA vs NVTA

Side-by-side comparison of Natera Inc. (NTRA) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NTRA and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
  • NTRA is the larger of the two at $31.81B, about 13.7x NVTA ($2.31B).
  • NTRA has hit the wire 16 times in the past 4 weeks while NVTA has been quiet.
  • NTRA has more recent analyst coverage (25 ratings vs 18 for NVTA).
MetricNTRANVTA
Company
Natera Inc.
Invitae Corporation
Price
$222.11+4.79%
$0.09-77.21%
Market cap
$31.81B
$2.31B
1M return
+7.37%
-
1Y return
+34.11%
-
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NYSE
IPO
2015
2015
News (4w)
16
0
Recent ratings
25
18
NTRA

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

NVTA

Invitae Corporation

Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Latest NTRA

Latest NVTA